标题/作者	年份
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130	2019
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031	2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138	2019
Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum WT Cefalu, S Kaul, HC Gerstein, RR Holman, B Zinman, JS Skyler, ... Diabetes care 41 (1), 14-31	2018
2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways SR Das, BM Everett, KK Birtcher, JM Brown, WT Cefalu, JL Januzzi, ... Journal of the American College of Cardiology 72 (24), 3200-3223	2018
Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents A Di Pino, RA DeFronzo Endocrine reviews 40 (6), 1447-1467	2019
The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE−/− and LDLr−/− mice by a mechanism that includes inflammatory pathways G Rakipovski, B Rolin, J Nøhr, I Klewe, KS Frederiksen, R Augustin, ... JACC: Basic to Translational Science 3 (6), 844-857	2018
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial B Ludvik, JP Frías, FJ Tinahones, J Wainstein, H Jiang, KE Robertson, ... The lancet Diabetes & endocrinology 6 (5), 370-381	2018
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA P Sarafidis, CJ Ferro, E Morales, A Ortiz, J Malyszko, R Hojs, K Khazim, ... Nephrology Dialysis Transplantation 34 (2), 208-230	2019
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020 R Chawla, SV Madhu, BM Makkar, S Ghosh, B Saboo, S Kalra, ... Indian journal of endocrinology and metabolism 24 (1), 1	2020
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data AC Sposito, O Berwanger, LSF de Carvalho, JFK Saraiva Cardiovascular diabetology 17 (1), 1-19	2018
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis Y Fei, MF Tsoi, BMY Cheung Cardiovascular diabetology 18 (1), 1-13	2019
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association JJ Joseph, P Deedwania, T Acharya, D Aguilar, DL Bhatt, DA Chyun, ... Circulation 145 (9), e722-e759	2022
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial SC Bain, O Mosenzon, R Arechavaleta, P Bogdański, A Comlekci, ... Diabetes, Obesity and Metabolism 21 (3), 499-508	2019
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial HC Gerstein, R Hart, HM Colhoun, R Diaz, M Lakshmanan, FT Botros, ... The Lancet Diabetes & Endocrinology 8 (2), 106-114	2020
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial LA Leiter, SC Bain, I Hramiak, E Jódar, S Madsbad, T Gondolf, T Hansen, ... Cardiovascular diabetology 18 (1), 1-12	2019
Management of hypoglycemia in older adults with type 2 diabetes J Freeman Postgraduate Medicine 131 (4), 241-250	2019
Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review JI Mechanick, ME Farkouh, JD Newman, WT Garvey Journal of the American College of Cardiology 75 (5), 539-555	2020
Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists AJ Scheen Diabetes Research and Clinical Practice 143, 88-100	2018
Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis S McGurnaghan, LAK Blackbourn, E Mocevic, U Haagen Panton, ... Diabetic Medicine 36 (6), 718-725	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。